Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $9.17

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $9.17.

SANA has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They set an “overweight” rating and a $12.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a research report on Thursday, April 24th.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in SANA. Bank of New York Mellon Corp lifted its position in Sana Biotechnology by 3.0% during the fourth quarter. Bank of New York Mellon Corp now owns 336,828 shares of the company’s stock worth $549,000 after buying an additional 9,905 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sana Biotechnology by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company’s stock worth $1,722,000 after buying an additional 8,666 shares in the last quarter. Corient Private Wealth LLC lifted its position in Sana Biotechnology by 161.7% during the fourth quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock worth $1,928,000 after buying an additional 730,699 shares in the last quarter. Teacher Retirement System of Texas raised its position in Sana Biotechnology by 20.3% in the fourth quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company’s stock valued at $60,000 after purchasing an additional 6,209 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in Sana Biotechnology in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of SANA opened at $4.63 on Thursday. The business has a 50-day moving average of $2.78 and a 200 day moving average of $2.56. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The firm has a market cap of $1.04 billion, a P/E ratio of -5.26 and a beta of 1.86.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. As a group, research analysts predict that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.